News Feed
Events By OncoDaily
OncoGrants
OncoDaily TV
NewsLetter
Voices
Not To Miss
FDA Approvals
New Paper Alert
OncoDaily 100
Community
OncoDaily Magazine
Career Updates
Oncology Drugs
Dialogues
Stories

Celebrities and Cancer
Immune Oncology
Breast Oncology
Gastrointestinal Oncology
Genitourinary Oncology
Lung Oncology
Hematology
Radiotherapy
Cancer Types
Science
Trial Updates
ASCO
ESMO
ESO
MASCC
Cancer Center Near Me
Oncologist Near Me

Childhood Cancer
Health Policy
Hall of Fame
OncoIndustry
Public Health
Oncology Tech
Blog Posts
Global Cancer Movement
History
Oncolibrary
OncoThon 2025

OncoDaily Washington DC
OncoDaily India
OncoDaily Brazil
OncoDaily Algeria
OncoDaily Kenya

Yvonne Awards
OncoDaily Party
How I Treat
O Series
Global Oncothon

OncoDaily Medical Journal
OncoDaily Newsletters
OncoDaily Magazine
CancerWorld Magazine
World Health Magazine
BIGR
Hemostasis Today
Fertility News

OncoDaily GI
OncoDaily Breast
OncoDaily IO
OncoDaily Lung
OncoDaily RT
OncoDaily GU
OncoDaily AI
OncoDaily Biotech
Hematology

Services
Partners
Contact us
About OncoDaily
P53 Inc
Privacy Policy
Editorial Policy
Disclaimer
Cookie Policy

Sep / 2026

September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

« Aug

Voices
Not To Miss
FDA Approvals
New Paper Alert
OncoDaily 100
Community
OncoDaily Magazine
Career Updates
Oncology Drugs
Dialogues
Stories

News Feed
Events By OncoDaily
OncoGrants
OncoDaily TV
NewsLetter

OncoDaily Newsletter

Subscribe to our newsletter

1 in 4 UK Royal Cancer Stories Contained Alarming Misinformation, Study Finds

1 in 4 UK Royal Cancer Stories Contained Alarming Misinformation, Study Finds

Highlights from SIOP 2026

Highlights from SIOP 2026

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer After Endocrine Therapy

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer After Endocrine Therapy

Laura Alder: New SCLC Data and Insights From WCLC26

Laura Alder: New SCLC Data and Insights From WCLC26

David Barbie: Newly Identified p53 Neoepitope and TCR Reveal a New Pathway of Tumor Immune Evasion

David Barbie: Newly Identified p53 Neoepitope and TCR Reveal a New Pathway of Tumor Immune Evasion

Laura Towart: Vivan Therapeutics Generates 50M+ Genotype-Resolved Tumour–Drug Datapoints

Laura Towart: Vivan Therapeutics Generates 50M+ Genotype-Resolved Tumour–Drug Datapoints

Fabrice Barlesi: Gustave Roussy Ranked 3rd in the World Among the Best Oncology Hospitals

Fabrice Barlesi: Gustave Roussy Ranked 3rd in the World Among the Best Oncology Hospitals

Gevorg Tamamyan: Honored to Co-Chair the Cooperative Group With ACS Panel at the WIN Symposium

Gevorg Tamamyan: Honored to Co-Chair the Cooperative Group With ACS Panel at the WIN Symposium

ERC

Jun 27, 2026 7:58 am

Voices

Mark Lawler: European Cancer Research and Innovation Discussed at ERC Event

Mark Lawler: European Cancer Research and Innovation Discussed at ERC Event

Sep 14, 2025 2:49 pm

Voices

Dr. Elsa Bernard Receives Prestigious ERC Starting Grant – Gustave Roussy

Dr. Elsa Bernard Receives Prestigious ERC Starting Grant – Gustave Roussy

Feb 23, 2025 10:51 am

Science

Karin Langenberg-Ververgaert: Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines

Karin Langenberg-Ververgaert: Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines

Apr 14, 2024 10:50 pm

Blog Posts

The Crick and UCL group leaders have received new European Research Council Advanced Grants

The Crick and UCL group leaders have received new European Research Council Advanced Grants

Apr 9, 2024 1:03 pm

Insight

Triantafyllos Stylianopoulos: The role of the mast cells in reprogramming the tumor micro-environment

Triantafyllos Stylianopoulos: The role of the mast cells in reprogramming the tumor micro-environment

Jul 9, 2023 9:54 am

Blog Posts

Our new study on reprogramming cancer cells into antigen-presenting dendritic cells (Tumor-APCs) is out at Science Immunology – Filipe Pereira

Our new study on reprogramming cancer cells into antigen-presenting dendritic cells (Tumor-APCs) is out at Science Immunology – Filipe Pereira

Headlines

Robin Zon: ASCO Highlights Medicaid Policy Changes and Continuity of Cancer Care

2026 Curebound Cancer Challenge Participants Raise $3.8 Million to Accelerate Cancer Cures

Zainab Shinkafi-Bagudu: Renewed Hope for Nigerian Cancer Patients

The Cancer Medicines Already Exist, but They Were Not Designed for Children - WHO Targets the Formulation Gap

Luke Thomas: What Do Children With Cancer Need Most?

CancerWorld OncoDaily Medical Journal Hemostasis Today OncoDaily IO OncoDaily GI OncoDailyTV

OncoDaily™ | © 2023 - 2025

All rights reserved. Unauthorized reproduction, distribution, or transmission of any content on OncoDaily.com is strictly prohibited. For permission requests or inquiries, please contact OncoDaily directly. By accessing and using OncoDaily.com, you acknowledge and agree to comply with this copyright notice, as well as our Privacy Policy, Editorial Policy, Cookie Policy, and Disclaimer. Continued use of this website constitutes acceptance of all such terms and policies.

Phone number: +1 978 717 48 84

Email: info@oncodaily.com

About Privacy Policy Editorial Policy Cookie Policy Disclaimer

Crafted by Matemat

Oncology OncoDaily cancer Breast Cancer cancer care ASCO Lung cancer fight against cancer Cancer research Global fight against cancer Headlines immunotherapy ESMO NSCLC cancer treatment MD Anderson Cancer Center clinical trials colorectal cancer cancer awareness prostate cancer FDA Childhood Cancer Research UICC AACR ASCO24 chemotherapy Pancreatic Cancer radiation oncology Dana-Farber Cancer Institute Precision Oncology AI American Cancer Society Robert Orlowski SIOP American Society of Clinical Oncology NCI European Cancer Organisation National Cancer Institute WHO radiotherapy Myeloma Paper of the Day cervical cancer IASLC Paolo Tarantino Myeloma Vivek Subbiah bladder cancer multiple myeloma Memorial Sloan Kettering Cancer Center

European School of Oncology

Sitemap

Hemostasis Today

Fertility News

Oncodaily Journal

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options
Manage services
Manage {vendor_count} vendors
Read more about these purposes

View preferences

{title}
{title}
{title}